Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Acronyms MERIT-2
- Sponsors Actelion Pharmaceuticals
- 21 Jun 2017 Planned End Date changed from 1 Jun 2018 to 28 Sep 2018.
- 21 Jun 2017 Planned primary completion date changed from 1 Jun 2018 to 28 Sep 2018.
- 21 Oct 2016 Status changed from recruiting to active, no longer recruiting.